You could be here for many reasons. Perhaps you know someone living with diabetes, and have developed a solution with them in mind, or you have worked in the healthcare space for years and want to address a clear unmet need. Either way, we want to enable people like you, who are innovating to improve the wellbeing of people living with diabetes around the world.
That is why we are making it possible for different types of apps, devices or systems to connect to Novo Nordisk smart insulin pens.
Our smart insulin pens automatically record how much insulin someone takes and when they take it, which can reduce the burden of manual dose logging for people using Novo Nordisk insulins.
Early data also indicate that data generated by a smart insulin pen can give people the information they need to make better diabetes management decisions, ultimately improving their health outcomes. (Reference Diabetes Technol Ther. 2020 Oct; 22(10):709-718. Adolfsson et.al.)
The smart insulin pens NovoPen® 6 and NovoPen Echo® Plus are mechanical durable injection devices with variable dose setting capabilities:
The built-in electronics can register the time of the injected dose and the dose size; these registrations are kept in a ‘dose log’ where the last 800 injections can be retrieved wirelessly, using Near Field Communication (NFC) technology.
NovoPen® 6 & NovoPen Echo® Plus are CE marked.
NovoPen® 6 & NovoPen Echo® Plus are currently not approved in the US.
Countless people and companies are developing modern solutions for managing diabetes, and the number of apps, devices and ideas is growing by the minute. People deserve the freedom to decide which solution works best for them. That is why we would like to make it possible for your solution to connect with our smart insulin pens.
Once you register and have signed the agreement for use of the pen specifications and potentially a data sharing agreement, you will receive documentation to guide you in establishing a connection between your app, device or system and NovoPen® 6 and / or NovoPen Echo® Plus. In addition, you will receive access to a list of common technical questions and answers.
Novo Nordisk will not assess, check nor scrutinize your solution from a quality, legal or regulatory view, nor will it perform checks on how source code has been implemented. Moreover, you must always make it clear to users and/or patients that Novo Nordisk has not performed safety checks on your solution.
You as a developer therefore assume full legal and regulatory responsibility for your solution and its suitability for its intended use and you must acknowledge this as part of the registration process, and that you are the legal manufacturer of the solution.
Insulin is an essential life-saving drug for many with a narrow therapeutic range, meaning that mistakes in dosing can lead to serious side effects including fatality. It is therefore essential that apps displaying insulin dosing data are developed with a rigorous risk analysis and mitigation plan as per regulatory requirements.
Working in the healthcare space, we all have a great responsibility to ensure that people can rely on and trust the services they use. We take this responsibility very seriously and ask that you do as well.